[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429718":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":66,"collaborators":24,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":24,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":24,"enrollmentInfo":77,"targetDuration":24,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":24,"overallStatus":47,"whyStopped":24,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Almond oil","EXPERIMENTAL","Almond Oil Pressed Cold",[13],"Other: Almond Oil",{"label":15,"type":16,"description":17,"interventionNames":18},"Hydroquinone","ACTIVE_COMPARATOR","Hydroquinone 2% cream",[19],"Drug: Hydroquinone Topical",[21,25],{"type":6,"name":22,"description":9,"armGroupLabels":23,"otherNames":24},"Almond Oil",[9],null,{"type":26,"name":27,"description":17,"armGroupLabels":28,"otherNames":29},"DRUG","Hydroquinone Topical",[15],[15],[31],{"name":32,"affiliation":33,"role":34},"Raja Sivamani, MD MS AP","UC Davis Dermatology","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":24,"email":40},"Iryna Rybak","CONTACT","916-551-2636","irybak@ucdavis.edu",{"name":42,"role":38,"phone":24,"phoneExt":24,"email":43},"Alexis Carrington","aecarrington@ucdavis.edu",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"UC Davis Department of Dermatology, Clinical Trials Unit","RECRUITING","Sacramento","California","95816","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-121.4944,38.58157,{"lat":57,"lon":56},[60,62,64],{"name":61,"role":38,"phone":39,"phoneExt":24,"email":40},"Iryna Rybak, BS",{"name":63,"role":38,"phone":39,"phoneExt":24,"email":43},"Alexis Carrington, MD",{"name":65,"role":34,"phone":24,"phoneExt":24,"email":24},"Raja K Sivamani, M.D.",{"type":67,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100429718","phase-4-prospective-evaluation-of-topical-almond-oil-vs-hydroquinone-100429718",false,"NCT04875715","Prospective Evaluation of Topical Almond Oil vs Hydroquinone","Prospective Evaluation of Topical Almond Oil vs Hydroquinone on the Appearance of Facial Pigmentation and the Stability of the Microbiome","Inclusion Criteria:\n\n* Premenopausal women of Fitzpatrick skin types 3 to 6\n\nExclusion Criteria:\n\n* Those with a nut allergy\n* Smoking is an independent risk factor and serves as a confounder for the development of facial aging \\[18\\]. Therefore current smokers, those that have smoked within the past year, and former smokers with greater than a 20 pack year history of smoking will be excluded.\n* Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndrome) will be excluded as this can be a confounder for facial photoaging.\n* Hormonal medications or therapies will not be allowed unless they have been stable on their medications for at least 2 months. Examples include oral contraceptives, progesterone-based injections, and estrogen based hormonal replacement therapy.\n* Those who have undergone any cosmetic procedures to the face in the 4 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment will also not be eligible.\n* Individuals who are unwilling to discontinue vitamin E containing supplements and food sources during the washout and intervention.\n* Individual who are unwilling to discontinue topical cosmetic products during the duration of the study.\n* Individuals who are not willing to engage in a two-week washout on topical treatments known to affect facial pigmentation and these agents will be restricted during the study period as well. These include topicals that contain:\n\n  * Retinoids such as tretinoin, adapalene, retinol.\n  * Antioxidant ingredients such as vitamin C or vitamin E.\n  * Pigment-reducing agents such as hydroquinone, azelaic acid, kojic acid per the discretion of the investigator except for the hydroquinone that is provided in this study.\n  * Topicals that contain a nut oil or nut extract as part of their ingredient list.\n* Furthermore, subjects will be asked to refrain from use of any other topical products for one week prior to each visit apart from the study agents supplied from this study.","FEMALE","18 Years",{"count":78,"type":79},50,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The purpose of this study is to analyze facial pigmentation and skin microbiome changes after topical almond oil application, compared to the use of topical hydroquinone.",[85],"Skin Pigmentation","2025-09-10",{"date":88,"type":89},"2025-09-12","ACTUAL",{"date":91,"type":89},"2021-07-01",{"date":93,"type":79},"2026-08-01",{"name":5,"class":6},1]